Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

Inclusion Criteria: * Understand the nature of the study and sign informed consent. * Diagnosis of open angle glaucoma or ocular hypertension. * Currently on PGA monotherapy or PGA + alpha-1/beta blocker or PGA + alpha-2 agonist at screening visit, and allowed to instill only PGA for 4 weeks until the baseline visit. * Intraocular pressure (IOP) ≥ 15 mmHg (at least one same eye) at the baseline visit. * Other protocol-specified inclusion criteria may apply. Exclusion Criteria: * History of bronchial asthma, bronchospasm, or serious chronic obstruction pulmonary disease. * Uncontrolled heart failure, sinus bradycardia, A-V block (II, III grade), cardiogenic shock, right heart failure due to pulmonary hypertension or congestive heart failure. * History of hypersensitivity to any of the excipients of the study medications. * Severe renal function disorders, diabetic ketoacidosis and metabolic acidosis, uncontrolled diabetes, or hepatic disorders. * Corneal disorder or history of chronic, recurrent or current severe inflammatory eye disease in either eye. * History of ocular trauma in either eye within 6 months prior to the screening examination. * Ocular infection or ocular inflammation in either eye. * History of or current clinically significant or progressive retinal disease in either eye. * Intraocular surgery in either eye within 6 months prior to the screening examination. * Ocular laser surgery in either eye within 3 months prior to the screening examination. * Any abnormality preventing reliable applanation tonometry of either eye. * Best-corrected visual acuity (BCVA) worse than 0.2 score (decimal visual acuity) in either eye. * Severe visual field loss in either eye. * Use of prohibited medication, as specified in the protocol. * Pregnant, lactating, or intending to become pregnant during the study period. * Currently on therapy or have been on therapy with another investigational agent within 30 days prior to the screening examination. * History of or current evidence of a severe illness or any other condition which would make the subject, in the opinion of the investigator, unsuitable for the study. * Other protocol-specified exclusion criteria may apply.